PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17631668-6 2008 The results showed that metabolic inhibitor KCN and P-glycoprotein inhibitor verapamil could increase berberine concentration within the neurons, indicating that efflux of berberine was energy-dependent and P-glycoprotein was likely to be involved. Berberine 102-111 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 52-66 32957491-1 2020 We aimed to develop a berberine formulation to enhance the intestinal absorption and plasma concentrations of berberine through the inhibition of P-glycoprotein (P-gp)-mediated efflux and the intestinal metabolism of berberine in rats. Berberine 110-119 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 162-166 32957491-1 2020 We aimed to develop a berberine formulation to enhance the intestinal absorption and plasma concentrations of berberine through the inhibition of P-glycoprotein (P-gp)-mediated efflux and the intestinal metabolism of berberine in rats. Berberine 110-119 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 146-160 32957491-1 2020 We aimed to develop a berberine formulation to enhance the intestinal absorption and plasma concentrations of berberine through the inhibition of P-glycoprotein (P-gp)-mediated efflux and the intestinal metabolism of berberine in rats. Berberine 110-119 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 162-166 32957491-4 2020 This berberine mixed micelle formulation had a mean size of 12 nm and increased the cellular accumulation of digoxin via P-gp inhibition. Berberine 5-14 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 121-125 32957491-7 2020 The plasma exposure of berberine was significantly greater in rats administered the berberine formulation compared to rats administered only berberine, which could be attributed to the increased berberine absorption by inhibiting the P-gp-mediated berberine efflux and intestinal berberine metabolism by berberine formulation. Berberine 23-32 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 234-238 32957491-7 2020 The plasma exposure of berberine was significantly greater in rats administered the berberine formulation compared to rats administered only berberine, which could be attributed to the increased berberine absorption by inhibiting the P-gp-mediated berberine efflux and intestinal berberine metabolism by berberine formulation. Berberine 84-93 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 234-238 32957491-7 2020 The plasma exposure of berberine was significantly greater in rats administered the berberine formulation compared to rats administered only berberine, which could be attributed to the increased berberine absorption by inhibiting the P-gp-mediated berberine efflux and intestinal berberine metabolism by berberine formulation. Berberine 84-93 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 234-238 32957491-7 2020 The plasma exposure of berberine was significantly greater in rats administered the berberine formulation compared to rats administered only berberine, which could be attributed to the increased berberine absorption by inhibiting the P-gp-mediated berberine efflux and intestinal berberine metabolism by berberine formulation. Berberine 84-93 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 234-238 32957491-7 2020 The plasma exposure of berberine was significantly greater in rats administered the berberine formulation compared to rats administered only berberine, which could be attributed to the increased berberine absorption by inhibiting the P-gp-mediated berberine efflux and intestinal berberine metabolism by berberine formulation. Berberine 84-93 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 234-238 32957491-7 2020 The plasma exposure of berberine was significantly greater in rats administered the berberine formulation compared to rats administered only berberine, which could be attributed to the increased berberine absorption by inhibiting the P-gp-mediated berberine efflux and intestinal berberine metabolism by berberine formulation. Berberine 84-93 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 234-238 32957491-7 2020 The plasma exposure of berberine was significantly greater in rats administered the berberine formulation compared to rats administered only berberine, which could be attributed to the increased berberine absorption by inhibiting the P-gp-mediated berberine efflux and intestinal berberine metabolism by berberine formulation. Berberine 84-93 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 234-238 32957491-8 2020 In conclusion, we successfully prepared berberine mixed micelle formulation using P85 and tween 80 that has inhibitory potential for P-gp and CYPs (CYP2C19, 2D6, and 3A4) and increased the berberine plasma exposure. Berberine 40-49 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 133-137 29679725-14 2018 CONCLUSIONS: The enhanced articular distribution of berberine in SMW was attributed to the lower-guiding effect of ABR, which could evidently increase the plasma concentration of berberine, improve the supply of blood of inflamed joint, reduce the distribution of berberine in heart and lung and significantly inhibit the MDR1 mRNA and P-gp expression of synovial tissues of knee joints in AGA rats. Berberine 52-61 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 322-326 29679725-14 2018 CONCLUSIONS: The enhanced articular distribution of berberine in SMW was attributed to the lower-guiding effect of ABR, which could evidently increase the plasma concentration of berberine, improve the supply of blood of inflamed joint, reduce the distribution of berberine in heart and lung and significantly inhibit the MDR1 mRNA and P-gp expression of synovial tissues of knee joints in AGA rats. Berberine 52-61 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 336-340 29703381-7 2018 Cell study indicated that CR decoction, berberine, coptisine, palmatine all activated the efflux transport of P-gp. Berberine 40-49 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 110-114 26446867-0 2016 Possible role of P-glycoprotein in the neuroprotective mechanism of berberine in intracerebroventricular streptozotocin-induced cognitive dysfunction. Berberine 68-77 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 17-31 26446867-2 2016 However, the neurological mechanism of berberine remains untapped in the light of its P-glycoprotein (P-gp)-mediated gut efflux properties responsible for reduced bioavailability. Berberine 39-48 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 86-100 26446867-2 2016 However, the neurological mechanism of berberine remains untapped in the light of its P-glycoprotein (P-gp)-mediated gut efflux properties responsible for reduced bioavailability. Berberine 39-48 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 102-106 26446867-10 2016 CONCLUSION: The augmentative outcome of verapamil on the neuroprotective effect of berberine can be speculated due to the inhibition of P-gp efflux mechanism and the prevention of calcium homeostasis alteration. Berberine 83-92 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 136-140 32957491-0 2020 Enhanced Intestinal Absorption and Pharmacokinetic Modulation of Berberine and Its Metabolites through the Inhibition of P-Glycoprotein and Intestinal Metabolism in Rats Using a Berberine Mixed Micelle Formulation. Berberine 65-74 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 121-135 32957491-0 2020 Enhanced Intestinal Absorption and Pharmacokinetic Modulation of Berberine and Its Metabolites through the Inhibition of P-Glycoprotein and Intestinal Metabolism in Rats Using a Berberine Mixed Micelle Formulation. Berberine 178-187 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 121-135 32957491-1 2020 We aimed to develop a berberine formulation to enhance the intestinal absorption and plasma concentrations of berberine through the inhibition of P-glycoprotein (P-gp)-mediated efflux and the intestinal metabolism of berberine in rats. Berberine 22-31 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 146-160 32957491-1 2020 We aimed to develop a berberine formulation to enhance the intestinal absorption and plasma concentrations of berberine through the inhibition of P-glycoprotein (P-gp)-mediated efflux and the intestinal metabolism of berberine in rats. Berberine 22-31 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 162-166 32957491-1 2020 We aimed to develop a berberine formulation to enhance the intestinal absorption and plasma concentrations of berberine through the inhibition of P-glycoprotein (P-gp)-mediated efflux and the intestinal metabolism of berberine in rats. Berberine 110-119 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 146-160 23133498-12 2012 Our results suggest that the expression of P-glycoprotein and organic anion and/or organic cation transporters (OAT/OCT) could take a role in reduced oral bioavailability of ciprofloxacin by berberine and HR. Berberine 191-200 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 43-57 20410605-6 2010 In contrast, berberine and palmatine slightly upregulated the mRNAs of Mdr1a and Mdr1b, but failed to induce Mdr1a/1b protein expression or stimulate rhodamine 123 efflux. Berberine 13-22 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 81-86 17631668-6 2008 The results showed that metabolic inhibitor KCN and P-glycoprotein inhibitor verapamil could increase berberine concentration within the neurons, indicating that efflux of berberine was energy-dependent and P-glycoprotein was likely to be involved. Berberine 102-111 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 207-221 17631668-6 2008 The results showed that metabolic inhibitor KCN and P-glycoprotein inhibitor verapamil could increase berberine concentration within the neurons, indicating that efflux of berberine was energy-dependent and P-glycoprotein was likely to be involved. Berberine 172-181 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 52-66 12530470-2 2002 The aim of this study was to use the P-glycoprotein (P-glycoprotein) inhibitors cyclosporin A, verapamil and the monoclonal antibody C219 in in vivo and in vitro models of intestinal absorption to determine the role of P-glycoprotein in berberine absorption. Berberine 237-246 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 53-67 15039293-5 2004 Moreover, berberine was processed through hepatobiliary excretion against a concentration gradient based on the bile-to-blood distribution ratio (AUC(bile)/AUC(blood)); the active berberine efflux might be affected by P-gp and OCT since coadministration of berberine and CsA or quinidine at the same dosage of 10 mg kg(-1) significantly decreased the berberine amount in bile. Berberine 10-19 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 218-222 15039293-5 2004 Moreover, berberine was processed through hepatobiliary excretion against a concentration gradient based on the bile-to-blood distribution ratio (AUC(bile)/AUC(blood)); the active berberine efflux might be affected by P-gp and OCT since coadministration of berberine and CsA or quinidine at the same dosage of 10 mg kg(-1) significantly decreased the berberine amount in bile. Berberine 180-189 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 218-222 15039293-5 2004 Moreover, berberine was processed through hepatobiliary excretion against a concentration gradient based on the bile-to-blood distribution ratio (AUC(bile)/AUC(blood)); the active berberine efflux might be affected by P-gp and OCT since coadministration of berberine and CsA or quinidine at the same dosage of 10 mg kg(-1) significantly decreased the berberine amount in bile. Berberine 180-189 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 218-222 15039293-5 2004 Moreover, berberine was processed through hepatobiliary excretion against a concentration gradient based on the bile-to-blood distribution ratio (AUC(bile)/AUC(blood)); the active berberine efflux might be affected by P-gp and OCT since coadministration of berberine and CsA or quinidine at the same dosage of 10 mg kg(-1) significantly decreased the berberine amount in bile. Berberine 180-189 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 218-222 12530470-0 2002 The involvement of P-glycoprotein in berberine absorption. Berberine 37-46 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 19-33 12530470-2 2002 The aim of this study was to use the P-glycoprotein (P-glycoprotein) inhibitors cyclosporin A, verapamil and the monoclonal antibody C219 in in vivo and in vitro models of intestinal absorption to determine the role of P-glycoprotein in berberine absorption. Berberine 237-246 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 37-51 12530470-2 2002 The aim of this study was to use the P-glycoprotein (P-glycoprotein) inhibitors cyclosporin A, verapamil and the monoclonal antibody C219 in in vivo and in vitro models of intestinal absorption to determine the role of P-glycoprotein in berberine absorption. Berberine 237-246 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 53-67 12530470-3 2002 In the rat recirculating perfusion model, berberine absorption was improved 6-times by P-glycoprotein inhibitors. Berberine 42-51 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 87-101 12530470-7 2002 P-glycoprotein appears to contribute to the poor intestinal absorption of berberine which suggests P-glycoprotein inhibitors could be of therapeutic value by improving its bioavailability. Berberine 74-83 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-14 12530470-7 2002 P-glycoprotein appears to contribute to the poor intestinal absorption of berberine which suggests P-glycoprotein inhibitors could be of therapeutic value by improving its bioavailability. Berberine 74-83 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 99-113